Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma

International Journal of Clinical Practice

Volumn 57, Issue 10, 2003, Pages 875-878

  Sodhi, P K ^a   Pandey, R M ^b   Ratan, S K ^c  

^a SAFDARJUNG HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRIMONIDINE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; PROSTAGLANDIN F; QUINOXALINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE; TIMOLOL;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BURNING SENSATION; CHILD; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; EYE COLOR; EYE IRRITATION; FEMALE; HEADACHE; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; STATISTICAL ANALYSIS; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; SULFONAMIDES; THIOPHENES; TREATMENT OUTCOME;

EID: 0346505225     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cantor LB, Burke J. Drug evaluation: pulmonary allergy, dermatology, gastrointestinal and arthritis. Brimonidine. Exp Opin Invest Drugs 1997; 6: 1063-1083.
2. Strahlman E, Vogel R, Tipping R, Clineschmidt CM, the Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996; 103: 1283-1293.
3. Altuna JC, Greenfield DS, Wand M et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J Glaucoma 1999; 8: 199-203.
4. Wayman LL, Larsson L-I, Maus TL, Brubaker RF. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115: 1368-1371.
5. DesMarchais B, Candal E, Weitzman M, Bruceshields M. Effect of latanoprost as adjunctive therapy. Can J Ophthalmol 2000; 35: 214-217.
6. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001; 10: 220-226.
7. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514-1517.
8. Konstas AGP, Lake S, Maltezos AC et al. Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye 2001; 15: 59-62.
9. Stewart WC, Sharpe ED, Day DG et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.25 or dorzolamide 2% when added to a topical B-adrenergic blocker in patients with primary open angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16: 251-259.
10. Centofanti M, Manni G, Gregori D et al. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefe's Arch Clin Exp Ophthalmol 2000; 238: 302-305.
11. Adamsons I, Clineschmidt C, Polis A et al, and the additivity study group. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. J Glaucoma 1998; 7: 253-260.
12. Camras CB, and the US Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-147.
13. Stewart WC, Day DG, Sharpe ED et al. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 1999; 128: 692-696.
14. Smith SL, Sine CS, Pruitt CA, Stewart WC. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy. J Ocul Pharmacol Ther 1999; 15: 29-39.
15. Schwartzenberg GWS, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999; 106: 1616-1620.
16. Wayman LL, Larsson L-I, Maus TL, Brubaker RF. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Arch Ophthalmol 1998; 116: 1438-1440.
17. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10: 384-403.
18. Lee DA, Gornbein JA, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open angle glaucoma or ocular hypertension a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther 2000; 16: 3-18.
19. Derick RJ, Robin AL, Walters TR et al. Brimonidine tartarate: a one month dose response study. Ophthalmology 1997; 104: 131-136.
20. Fristrom B, Nilsson SEG. Intersection of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol 1993; 111: 662-665.
21. Hoyng PF, Rulo A, Greve E et al. The additive intraocular pressure lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol 1997; 41: S93-S98.
22. Adamsons IA, Polis A, Ostrov CS, Boyle JE. Two years safety study of dorzolamide as monotherapy and with timolol and pilocarpine. J Glaucoma 1998; 7: 395-401.
23. Watson PG, Stjernschantz J, the Latanoprost Study Group. A six month, randomized, double-masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-137.
24. Nardin G, Lewis EA, Keates E et al. Activity of the topical CAI MK-507 bid when added to timolol bid. Invest Ophthalmol Vis Sci 1991; 32(suppl): 989.
25. Watson PG. Latanoprost: two years' experience of its use in the United Kingdom. Ophthalmology 1998; 105: 82-87.
26. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41(suppl 1): S27-S37.
27. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha-2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma 1997; 6: 250-258.
28. Camras CB, Alm A, Watson P, Stjernschantz J, the Latanoprost Study Group. Latanoprost, a prostaglandin analog, for glaucoma therapy. Ophthalmology 1996; 103: 1916-1924.
29. Strahlman E, Tipping R, Vogel R et al. A double-masked, randomized, 1 year study comparing dorzolamide (Trusopt), timolol and betaxolol. Arch Ophthalmol 1995; 113: 1009-1016.
30. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996; 41(suppl 1): S39-S47.
31. Konstas AGP, Maltezos A, Bufidis T et al. Twenty four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open angle glaucoma. Eye 2000; 14: 73-77.